结核分枝杆菌耐喹诺酮临床分离株gyrA基因突变的研究

摘要/Abstract

摘要： 目的　了解结核分枝杆菌喹诺酮 (quinolones)耐药株耐药基因突变情况,评价其应用价值。方法通过 16SrRNA聚合酶链反应-单链构象多态性 (PCR SSCP)技术分析 77株分枝杆菌临床分离株；通过PCR SSCP和直接测序技术分析结核分枝杆菌的gyrA基因突变的情况。结果 75株为结核分枝杆菌复合群。 30株喹诺酮敏感株的 gyrA基因的SSCP图谱中,11株与H₃₇R_v相同,19株与卡介苗相同；与卡介苗 gyrA基因的SSCP图谱相同的敏感株 95位密码子为ACC,与H₃₇R_v该图谱相同的敏感株 95位密码子为AGC。 45株喹诺酮耐药株中,34株 (75.6%) gyrA基因SSCP图谱泳动异常,对 25株泳动异常、出现频率较高耐药株测序证实 15株 (44.1%)为 94位密码子GAC→GGC突变；10株 (29.4%)为 90位密码子GCG→GTG的突变。结论结核分枝杆菌耐喹诺酮与 gyrA基因突变有关,PCR SSCP可能成为测定结核分枝杆菌耐喹诺酮类药基因型的快速、简便的方法。

关键词: 分枝杆菌,结核, 喹诺酮, 药物耐受性, 聚合酶链反应, 多态性,单链构象

Abstract: Objective To observe the mutations of gyrA gene in M.Tuberculosis quinolones-resistant isolates,and to evaluate their clinical value.Methods 77 clinical isolates were identified for their mycobacteria species,and were analyzed M.tuberculosis gyrA genes by PCR-SSCP and PCR-direct sequencing.Results Seventy-five isolates were identified as M.tuberculosis.Of 30 quinolones-sensitive isolates,11 isolates had same gyrA SSCP profiles as H₃₇R_v,19 had same profiles as M.bovis BCG.The drug-sensitive isolates whose gyrA SSCP profiles was identical to H₃₇R_v were AGC at condon 95,the others were ACC at condon 95.Of 45 quinolones-resistant isolates,34 (75.6%) displayed abnormal gyrA SSCP profiles.25 clinicals of 2 kinds of gyrA SSCP profiles which appeared at a high frequency were sequenced.15 isolates had GAC→GGC mutation at condon 94;10 isolates had GCG→GTG mutation at condon 90.Conclusion Quinolones resistances in some M.tuberculosis isolates were due to mutation on gyrA genes.PCR-SSCP method might become a simple and rapid diagnostic test for identification of genotypes of M.tuberculosis quinolones-resistance.

Key words: Mycobacterium tuberculosis, Quinolones, Drug-resistance, Polymerase chain reaction, Polymorphism,single-stranded conformational

安慧茹,王巍,李洪敏,梁建琴,刘真,李素梅,何珂,. 结核分枝杆菌耐喹诺酮临床分离株gyrA基因突变的研究[J]. 中国防痨杂志, 2004, 26(3): 129-132.

An Huiru,Wang Wei,Li Hongmin,et al.. Study on gyrA mutation in Mycobacterium tuberculosis quinolone-resistant isolates[J]. Chinese Journal of Antituberculosis, 2004, 26(3): 129-132.

参考文献

1 Ouabdesselam S, Hooper D C, Tankovic J, et al.Detection of gyrA and gyrB mutations in quinolone-resistant ctinical isolates of Escherichia coli by single-strand conformation polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations.Antimicrob Agents Chemother [J].1995,39(8)：1667～1670.
2 郑东钧，宋诗铎,祁伟,等.临床分离耐氟喹诺酮金黄色葡萄球菌的耐药机制研究[J].中华传染病杂志，1997,15:130～133.
3 吴雪琼、张俊仙、刘佳文等.PCR-SSCP分枝杆菌菌种初步鉴定方法的建立及其应用[J].中国现代医学杂志,2000，10(7):25～26.
4 Takiff H E, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations[J]. Antimicro Agents Chemother, 1994,38(4)：773～780.
5 Guillemin I, Cambau E and Jarlier V.Sequences of conserved region in the A subunit of DNA Gyrase from Nine Species of the Genus Mycobacterium: Phylogenetic analysis and implication for inrinsic susceptibility to quinolones[J]. Antimicrobial agents and chemotherapy,1995,39(9):2145～2149.
6 George J, Manavathu E K, Vakulenko,SB,et al. Characterization of fluoroquinolone-resistant mutant strains of mycobacterium tuberculosis selected in the laboratory and isolated from patients [J].Antimicrobial agents and chemotherapy.1995,39(8):1700～1703.
7 Kocagoz T, Hackbarth C, Unsal Z,et al. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant, mutants of mycobacterium tuberculosis H₃₇R_a [J]. Antimicrobial agents and chemotherapy,1996,46(8):1768～1774.
8 Onodera Y, Tanaka M and Sato K. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis[J]. Journal of Antimicrobial Chemot herapy,2001,47:447～450.
9 Jarlier V, and Nikaido H. Permeability barrier to hydrophilic solutes in Mycobacterium chelonei[J]. J Bacteriol,1990,172：1418～1423.
10 Takiff H E, Cimino M, Musso M C,et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis[J]. Proc. Natl. Acad. Sci. USA,1996，93:362～366.

[1]	李玉红, 梅金周, 苏伟, 阮云洲, 刘玉舒, 赵雁林, 刘小秋. 2015—2021年全国65岁及以上老年利福平耐药肺结核患者治疗转归及影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 408-415.
[2]	姜雪, 白云龙, 马建军, 安源, 杨帆, 赵庆龙. 2020—2023年吉林省利福平耐药肺结核患者诊治延迟现状及影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 416-424.
[3]	徐子安, 浦飞飞, 冯晶, 夏平. 高通量测序技术在骨关节结核诊疗中的研究进展[J]. 中国防痨杂志, 2025, 47(2): 224-230.
[4]	陈纪飞, 黄丽花, 罗兰波, 眭文娴, 逄宇, 刘爱梅. 舌拭子-PCR荧光探针法对肺结核诊断效能的评价[J]. 中国防痨杂志, 2025, 47(1): 51-60.
[5]	杨玉堂, 乔玉, 戴云鹏. 儿童耐药结核病的临床研究进展[J]. 中国防痨杂志, 2024, 46(S1): 319-321.
[6]	王小敏, 陈锦云, 曾昱芹, 马佺, 孔星星, 蒙建州, 卢水华. 《世界卫生组织结核病整合指南模块3:诊断——结核病检测的快速诊断》第三版解读[J]. 中国防痨杂志, 2024, 46(9): 1006-1022.
[7]	于兰, 陈双双, 王嫩寒, 田丽丽, 赵琰枫, 樊瑞芳, 刘海灿, 李传友, 代小伟. 利福平耐药结核分枝杆菌对氟喹诺酮类药物表型耐药与其基因突变的一致性研究[J]. 中国防痨杂志, 2024, 46(8): 942-950.
[8]	王嫩寒, 田丽丽, 陈双双, 赵琰枫, 樊瑞芳, 陈昊, 任怡宣, 张洁, 易俊莉, 杨新宇, 于兰, 丁北川, 李传友, 代小伟. 荧光PCR探针熔解曲线技术检测痰标本结核分枝杆菌利福平耐药性的研究[J]. 中国防痨杂志, 2023, 45(6): 583-588.
[9]	李红娜, 毛昕, 徐碧宇, 吴晨阳, 董丽儒, 宋旭东. 常见原位病理染色技术诊断肺结核的临床价值研究[J]. 中国防痨杂志, 2023, 45(5): 477-482.
[10]	詹建, 游国庆, 何霞, 孔珏颖, 刘文果, 冯鑫, 胡彦. 两种结核分枝杆菌氟喹诺酮类药物耐药性检测方法比较及不一致原因初探[J]. 中国防痨杂志, 2023, 45(11): 1058-1063.
[11]	魏淑贞, 赵永, 林建, 林淑芳, 戴志松. 2017—2019年福建省结核分枝杆菌分离株基因型特征及其耐药性分析[J]. 中国防痨杂志, 2023, 45(1): 73-78.
[12]	金龙, 田琦, 张宝庆, 邢海冬, 高明霞, 张秀英, 王利华, 张晓磊. 荧光PCR熔解曲线法检测耐多药肺结核患者对左氧氟沙星和莫西沙星耐药性的效能研究[J]. 中国防痨杂志, 2022, 44(2): 159-163.
[13]	孙雯娜, 张俊仙, 张秀爽, 王晓朦, 林文, 梁艳, 王杰, 吴雪琼. 两种分子药物敏感性试验与表型药物敏感性试验检测结核分枝杆菌耐药性的效能比较[J]. 中国防痨杂志, 2022, 44(10): 1016-1021.
[14]	石文卉, 初乃惠. 耐药肺结核患者氟喹诺酮类药物耐药情况及影响因素[J]. 中国防痨杂志, 2021, 43(9): 905-909.
[15]	李爱芳, 谈小文, 崔晓利, 康磊, 党丽云, 张耀辉, 杨翰. 荧光PCR熔解曲线法在非结核分枝杆菌菌种鉴定中的应用价值[J]. 中国防痨杂志, 2021, 43(7): 664-669.